title: Protection of mice against H. somni septicemia by vaccination with recombinant immunoglobulin binding protein subunits.
abstract: Histophilus somni causes bovine pneumonia as well as septicemia and its sequelae but mechanisms of virulence and protective immunity are poorly understood. Since surface immunoglobulin binding proteins are virulence factors, we addressed their role as protective antigens in a mouse model of H. somni septicemia. Immunoglobulin binding protein A (IbpA), has homology to Bordetella pertussis filamentous hemagglutinin and other large bacterial exoproteins. IbpA is a major surface antigen encoded by the ibpA gene with many domains that may be important in pathogenesis and immune protection. Three IbpA recombinant protein subunits, IbpA3, IbpA5 and IbpADR2 were chosen for study because of putative functional domains and motifs. These recombinant GST fusion subunit proteins were compared with GST (negative control), formalin-killed H. somni (commercial vaccine control), live H. somni (to induce convalescent immunity) and H. somni culture supernatant (containing IbpA shed from the bacterial surface). In vaccination/challenge studies, both live H. somni (convalescent immunity) and supernatant protected equally but formalin-killed H. somni and GST did not protect against septicemia. The DR2 and A3 subunits protected moderately well and induced antibody responses against supernatant antigen and the homologous subunit in ELISA but not against whole cell antigens. Supernatant immunization protected better than the IbpA subunit antigens and induced high antibody activity against both whole cells and supernatant antigens. The results indicate that culture supernatant antigens or perhaps recombinant IbpA subunits may be useful in H. somni vaccines. These studies also provide insight into the contribution of IbpA domains to pathogenesis of H. somni septicemia.
authors.affiliation: Department of Pathology, School of Medicine, University of California, San Diego, 200 West Arbor Drive, San Diego, CA 92103-8416, USA.
authors.forename: Roger S
authors.initials: RS
authors.lastname: Geertsema
authors.forename: Carolyn
authors.initials: C
authors.lastname: Worby
authors.forename: Robert P
authors.initials: RP
authors.lastname: Kruger
authors.forename: Yuichi
authors.initials: Y
authors.lastname: Tagawa
authors.forename: Riccardo
authors.initials: R
authors.lastname: Russo
authors.forename: D Scott
authors.initials: DS
authors.lastname: Herdman
authors.forename: Kimby
authors.initials: K
authors.lastname: Lo
authors.forename: Richard A
authors.initials: RA
authors.lastname: Kimball
authors.forename: Jack
authors.initials: J
authors.lastname: Dixon
authors.forename: Lynette B
authors.initials: LB
authors.lastname: Corbeil
mesh_terms: D000818:Animals; D000907:Antibodies, Bacterial / Q000097:blood; D001426:Bacterial Proteins / Q000235:genetics / Q000276:immunology*; D001428:Bacterial Vaccines / Q000235:genetics / Q000276:immunology*; D002417:Cattle; D002418:Cattle Diseases / Q000517:prevention & control*; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D051379:Mice; D015661:Pasteurellaceae / Q000235:genetics / Q000276:immunology*; D016871:Pasteurellaceae Infections / Q000517:prevention & control / Q000662:veterinary*; D018805:Sepsis / Q000517:prevention & control / Q000662:veterinary*; D012720:Severity of Illness Index; D016019:Survival Analysis; D014613:Vaccines, Attenuated / Q000276:immunology; D015164:Vaccines, Inactivated / Q000276:immunology; D014614:Vaccines, Synthetic / Q000235:genetics / Q000276:immunology
chemical_list: D000907:Antibodies, Bacterial; D001426:Bacterial Proteins; D001428:Bacterial Vaccines; D014613:Vaccines, Attenuated; D015164:Vaccines, Inactivated; D014614:Vaccines, Synthetic